CBT-004 is a potent multi-kinase inhibitor of VEGFRs, PDGFRs among other targets and can inhibit corneal neovascularization. CBT-004 is a unique topical formulation following 505b(2) regulatory pathway to treat pinguecula that currently has no approved drug treatment.
In animal models , CBT-004 has been demonstrated to be highly effective in reducing corneal neovascularization. In addition, clinical data shows CBT-004 is safe to use on humans. CBT-004 is in Phase II clinical trial.